RIGEL PHARMACEUTICALS INC — Director's Dealing 2025

Mar 20, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: RIGEL PHARMACEUTICALS INC (RIGL)
CIK: 0001034842
Period of Report: 2025-03-17

Reporting Person: Furey Raymond J. (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-03-17	Employee Stock Option (right to buy)	$9	A	9375	Acquired	2032-12-08	Common Stock (9375)	Direct
2025-03-17	Employee Stock Option (right to buy)	$12.7	A	7850	Acquired	2034-01-23	Common Stock (7850)	Direct

Footnotes

F1: The Reporting Person was granted a stock option with a performance-based condition with respect to 9,375 shares of the Issuer's common stock on December 8, 2022, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the "Reverse Stock Split"). The exercise price of this option is $9.00, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met.

F2: The option was fully vested on March 17, 2025, the date the determination was made that the performance metric had been met.

F3: The Reporting Person was granted a stock option with a performance-based condition with respect to 7,850 shares of the Issuer's common stock on January 23, 2024, as adjusted for the Reverse Stock Split. The exercise price of this option is $12.70, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met.